Author Archives: Scalper1
Allergan Beats Q3 Estimates Amid M&A, Pricing Talk
Specialty-drug giant Allergan (AGN) beat analysts’ Q3 estimates Wednesday as CEO Brent Saunders dodged questions about buyout talks with Pfizer (PFE) while defending the company’s drug-pricing strategies and distancing its model from its peer Valeant Pharmaceuticals International (VRX). Allergan’s sales rose 90% over the year-earlier quarter to $4.09 billion, about $50 million above analysts’ consensus, according to Thomson Reuters. Earnings
Facebook Q3 Earnings Expectations Remain Strong
As Facebook (FB) stock hovers near a record high, the company’s video ad sales and Instagram service will be in focus when the No. 1 social network posts third-quarter earnings after the close Wednesday. Facebook has taken a cautious approach in finding ways to make money from its platforms, and has only slowly rolled out video ads. Last quarter, though, Facebook increased the pace. In September, Facebook announced it was boosting efforts to cash